George Elston

“If I can add to that, I think because the topic switching comes up frequently, and that's been the history of how wet AMD is treated. The most recent drugs say, we last longer, use us, stop using the other programs.”

“So just to remind everyone, we actually had our state-of-the-art facility built to our spec several years ago. We've been in the facility for almost two years now.”

“We have our own state-of-the-art facility, so we do drug development at iPoint. So this facility was started four years ago. We have registration batches already on stability, and we are scaling up and preparing not just for building commercial supply but also being prepared for a pre-approval inspection.”

“Thank you, and thank you all for joining us on today's conference call to discuss iPoint's first quarter, 2026, financial results and recent corporate developments.”

“Obviously, most of it is on our clinical trials and also our preparation for the NDA and our commercial scale up for manufacturing, which is equally important because, you know, once we report our data this summer, everyone's going to say, where's your NDA?”